AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patient global impression of change (PGI-C) scoring
Description: The PGI-C scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) answering the question Since the start of the trial, my overall status has.
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patient global impression of severity (PGI-S) scoring
Description: The PGI-S scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) answering the question Please rate the severity of your disease right now.
Study NCT05435638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lesion photography
Description: High-quality photographic documentation of the treated lesions will be performed on screening, and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, pre-dose, if applicable.
Study NCT05435638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-001 1% cream 16 weeks treatment
Description: KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves.
Study NCT06573294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN1057
Description: Intravenous (IV) infusion
Study NCT05687890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of SC0062
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Study NCT05687890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of SC0062
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Study NCT05687890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0062 low dose
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Study NCT05687890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0062 medium dose
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Study NCT05687890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0062 high dose
Description: Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
Study NCT06155305 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Before initiating neoadjuvant therapy, patients diagnosed with breast cancer undergo a tumor biopsy. The tissue obtained from the biopsy is utilized to establish organoids and conduct drug testing.
Study NCT05684757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: Dietary Advice
Study NCT06515691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-TAPA block
Description: After the wound closure is completed and the patient is still under genaral anesthesia the M-TAPA block ill be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied on each side. The total volume will be 60 ml.
Study NCT06515691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain management
Description: ibuprofen 400mg (Ibuprofen-PF®) intravenous (IV), and tramadol (Contramal®) 100 mg IV will be administered to all patients 20 minutes before wound closure. After surgery, Ibuprofen 400 mg will be given three times a day. A patient-controlled analgesia (PCA) system containing 10 mcg/ml fentanyl will be provided to all patients without continuous infusion. Patients can administer boluses of 0.35 mcg/kg with a 15-minute lockout period and a maximum dose of 100 mcg per hour. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV tramadol (Contramal®) 100 mg will be given as a rescue analgesic.
Study NCT06515691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative pain management
Description: ibuprofen 400mg (Ibuprofen-PF®) intravenous (IV), and tramadol (Contramal®) 100 mg IV will be administered to all patients 20 minutes before wound closure. After surgery, Ibuprofen 400 mg will be given three times a day. A patient-controlled analgesia (PCA) system containing 10 mcg/ml fentanyl will be provided to all patients without continuous infusion. Patients can administer boluses of 0.35 mcg/kg with a 15-minute lockout period and a maximum dose of 100 mcg per hour. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV tramadol (Contramal®) 100 mg will be given as a rescue analgesic.
Study NCT06307886 — intervention group
Intervention type: PROCEDURE
Intervention: Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With manipulator
Description: patients who underwent laparoscopic hysterectomy with using uterine manipulator
Study NCT06307886 — intervention group
Intervention type: PROCEDURE
Intervention: lPatients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy without uterine manipulator
Description: patients who underwent laparoscopic hysterectomy without using uterine manipulator
Study NCT05102097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warm-up
Description: Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week
Study NCT05102097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Main exercise
Description: Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks
Study NCT05102097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cool down
Description: Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week
Study NCT05102097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
Study NCT05102097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
Study NCT05100628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 800 mg (400 mg suppository twice daily \[BID\]).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles.
Study NCT05100628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 1200 mg daily (600 mg suppository BID).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles.
Study NCT05100628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 1800 mg daily (600 mg suppository thrice daily).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles.
Study NCT05100628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: MTD of the combination of NOX66 and doxorubicin will be determined in the dose-escalation cohort of the study. The selected dose will be administered in combination with Doxorubicin.
Study NCT05100628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
Study NCT05733611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2
Description: Genetically modified herpes simplex type 1 virus
Study NCT05733611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP3
Description: Genetically modified herpes simplex type 1 virus
Study NCT05733611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: anti-PD-L1 monoclonal antibody
Study NCT05733611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: anti-VEGF therapy
Study NCT05903859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid 500 Milligrams (mg)
Description: Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.
Study NCT05903859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probenecid 250 Milligrams (mg)
Description: Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.
Study NCT05903859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
Study NCT05442853 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring
Description: Continuous glucose monitoring involves a wearable device that measures glucose with a sensor that is inserted subcutaneously. The sensor transmits data to receiving device that displays the glucose values.
Study NCT05442853 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point of care glucose monitoring
Description: Point of care glucose monitoring involves use of an external device that can provide glucose readings at a patient's bedside. These devices require a small blood sample from venous, arterial, or capillary fingerstick blood. The blood sample is analyzed by the device and reports a glucose value within 5 minutes. This method of glucose monitoring is a mainstay and standard of care for most hospitals in the United States.
Study NCT05578651 — intervention group
Intervention type: DEVICE
Intervention: SternaLock XP
Description: Plating system with cable cerclage bands that is used in the stabilization and fixation of fractures of the anterior chest wall, including sternal fixation following sternotomy
Study NCT04731818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZB-06
Description: ZB-06 is a polyvinyl alcohol-based film containing 20 mg of human contraceptive antibody (HCA) for topical intravaginal administration.
Study NCT04790344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational LUX-Dx ICM Implant
Description: All subject will receive an investigational version of the LUX-Dx ICM device.
Study NCT05324410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-840
Description: Solution for oral administration.
Study NCT06128252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine
Description: Taurine supplementation in tablets of 1.0 gram of taurine powder. Dosage: 3.0 gram/day. Frequency: 3 time/day.
Study NCT06128252 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Serplulimab
Description: Serplulimab
Study NCT06128252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab
Study NCT06128252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX regimen
Description: Oxaliplatin + capecitabine
Study NCT06128252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX regimen
Description: Oxaliplatin + capecitabine
Study NCT06128252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Taurine placebo in tablets of 1.0 gram of starch powder. Dosage: 3.0 gram/day. Frequency: 3 time/day.
Study NCT06604988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-feedback intervention to promote positive parenting
Description: Each session will focus on three parental behaviours (that support child development) that have appeared clearly, frequently and consistently in the video (PICCOLO score of 2) in any of the 4 dimensions (affection, responsiveness, encouragement, teaching). Other aspects of parental behaviours that have scored 1 or 0 on the PICCOLO will also be considered, to increase their frequency or encourage their appearance. It is to be expected that all the behaviours collected in PICCOLO appear in one or more of the recordings, even if only occasionally. Behaviours that do not appear can be introduced through linking strategies with other behaviours in which parents show strength (for example, if a caregiver tends to name objects a lot, a link can be established between naming and asking the child the name of objects, if questions are behaviour that does not appear in the logs).~In each session, the caregiver is shown video clips that clearly show the positive parenting behaviours.
Study NCT06605963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPV-06
Description: 6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
Study NCT06605963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 subcutaneous injections at Day 1, Week 4, Week 24, Week 44, Week 64, Week 84
Study NCT05455788 — intervention group
Intervention type: DRUG
Intervention: Aminoglycoside
Description: injection of sewing ring of prosthetic valve with aminoglycoside
Study NCT05503641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive and psychomotor stimulation
Description: Each cognitive stimulation session aimed to maintain and/or improve cognition through memory, language, executive functions, attention, concentration, and perception activities. All the people in the two groups performed the same cognitive stimulation activities adapted to their cognitive and sensory abilities.~The psychomotricity sessions were aimed at maintaining and/or improving the motor, cognitive, social and affective functioning of the person through activities that work on postural tone, body scheme, laterality, fine and gross motor skills, balance, flexibility, among others, adding a cognitive component. All the psychomotricity activities were adapted to the motor and cognitive abilities of the users.
Study NCT05324410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-840 for oral administration.
Study NCT06634238 — intervention group
Intervention type: OTHER
Intervention: Incremental shuttle walk test
Description: Participants were recommended to wear comfortable clothing and appropriate shoes for the test. To minimize variability, one masked and one unmasked ISWT was performed on the same participant at the same time of day, one day apart
Study NCT05977374 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: experimental and conventional group
Description: Static stretchings of the lower limb, Ultrasound 1 MHz 1.5W/cm2 7 mins, knee isometrics, open chain activities, knee mobilizations grade 1 and 2, and home care plan.
Study NCT05977374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental and conventional group
Description: Static stretchings of the lower limb, Ultrasound 1 MHz 1.5W/cm2 7 mins, knee isometrics, open chain activities, knee mobilizations grade 1 and 2, and home care plan.
Study NCT04604067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days
Study NCT05863052 — intervention group
Intervention type: BIOLOGICAL
Intervention: Immunotherapy
Description: immunotherapy
Study NCT06604416 — intervention group
Intervention type: OTHER
Intervention: Forward walking
Description: The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate forward walking.
Study NCT06604416 — intervention group
Intervention type: OTHER
Intervention: Backward walking
Description: The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate backward walking.
Study NCT06605092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional stimulation
Description: Presentation of the paintings by distinguishing 3 conditions: (1) contemplating each painting (visual stimulation), (2) listening to the original music composed from each painting (auditory stimulation), (3) contemplating and listening to the association of each painting with each specific music (bimodal stimulation)
Study NCT06608810 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: nerve block with 0.5% ropivacaine
Description: General anesthesia tracheal intubation was used. Induction was performed with midazolam 0.05ml/kg, etomidate 0.3-0.4mg/kg, sufentanil 0.3μg/kg-0.4μg/kg, and rocuronium bromide 0.8mg/kg, and after sufficient oxygen and denitration, the tracheal tube was placed by visual laryngoscopy, and the position of the tube was determined by auscultation of the lungs to determine the position of the catheter, and the respiratory sounds of the sides were symmetrically clear, so that the catheter was fixed and mechanical ventilation was performed. Anesthesia was maintained with remifentanil 0.1～0.3μg/(kg-min), propofol 2\~4mg/(kg-h) rate microinfusion pump for continuous infusion. BIS was kept between 40\~60. Intraoperative rocuronium bromide was given intermittently to maintain muscle relaxation. Perioperative fluid replacement followed the (4:2:1) rule in all patients. For maintenance of hemodynamic stability, ephedrine or atropine was administered, at the anesthesiologist's discretion, if verified a
Study NCT04749368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-835 (VIR-2218)
Description: BRII-835 (VIR-2218) will be given by subcutaneous injection
Study NCT04749368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-179 (VBI-2601) with IFN-α
Description: BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection
Study NCT04749368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-179 (VBI-2601)
Description: BRII-179 (VBI-2601) will be administered by intramuscular injection
Study NCT06361706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-Enhanced Psychoeducational Program for Chronic Pain
Description: Participants undergo eight weekly sessions that include VR to learn pain physiology, mindfulness, and self-management techniques. Each session is 90 minutes, with 15-20 minutes of VR activities designed to complement the educational content. Activities simulate pain management exercises and mindfulness meditation. The program, led by pain management and VR specialists, aims to improve pain management skills, emotional well-being, and quality of life.
Study NCT06371209 — intervention group
Intervention type: PROCEDURE
Intervention: Modified Amputation
Description: Modified amputation procedure
Study NCT06371209 — intervention group
Intervention type: PROCEDURE
Intervention: Standard Amputation
Description: Standard amputation procedure
Study NCT04536350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aviptadil 67μg
Description: Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
Study NCT06607887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV antibiotic
Description: Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.
Study NCT06607887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antibiotic
Description: Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.
Study NCT04536350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.9% NaCl solution
Description: Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days